2.75 / AMA PRA Category 1 Credit(s)TM 2.75 / CE for Nurses 2.75 / CE for Pharmacists (0.275 CEUs)
This activity is jointly provided by Medical Education Resources (MER) and Educational Concepts in Medicine.
This activity is supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals, Inc
Dyslipidemia is a major risk factor for CHD, which remains the leading cause of death and disability in both men and women in the United States. Elevated LDL-C, low high-density lipoprotein cholesterol (HDL-C), and hypertriglyceridemia are among the disorders that encompass dyslipidemia. Although mean total cholesterol (TC) and LDL-C levels have declined over the past decade due to the use of lipid-lowering drugs, abnormal lipid levels remain a significant problem among patients with and without existing heart disease. In fact, recent estimates from the American Heart Association indicate that more than 98 million US adults still have elevated TC (≥200 mg/dL), more than 71 million have elevated LDL-C (≥130 mg/dL), and over 48 million have low HDL-C (<40 mg/dL).
While the prevalence of dyslipidemia remains high, screening, awareness, and treatment efforts continue to be suboptimal. According to data from the National Health and Nutrition Examination Survey (NHANES), among patients with elevated LDL-C, more than one-third had not been previously screened for dyslipidemia, approximately a quarter were screened but not told they had elevated LDL-C, and nearly 40% were not treated adequately. More recent data from NHANES showed that although the prevalence of dyslipidemia was 25% among individuals with no cardiovascular disease (CVD), only 63% of those were aware of their dyslipidemia and 38% were treated. Among patients with CVD, prevalence of dyslipidemia was 35%, but among these, only 83% were aware of their dyslipidemia and 76% treated.
This activity has been designed to meet the educational needs of primary care physicians, lipidologists, endocrinologists, cardiologists and high-level allied health professionals involved in the management of patients who would benefit from treatment of elevated low-density lipoprotein cholesterol (LDL-C) to reduce coronary heart disease (CHD) risk.
After completing this activity, the participant should be better able to:
Summarize the current status of screening, awareness, and treatment of individuals with dyslipidemia
Assess the challenges of achieving LDL-C treatment goals with existing statin therapies and strategies to overcome these challenges
Engage patients in a discussion on key guideline updates for the management of dyslipidemia/elevated LDL-C, including challenges and controversies surrounding their implementation
Describe the rationale for the use of PCSK9 inhibitors to lower LDL-C in patients with dyslipidemia
Identify the roles, benefits, and risks of PCSK9 inhibitors, MTP inhibitors, and Apo B inhibitors for LDL-C lowering in patients with dyslipidemia
Provide appropriate care and counsel for patients and their families
Conflict Of Interest Disclosure Policy
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Christie M. Ballantyne, MD, FACP, FACC Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology Department of Medicine Baylor College of Medicine Director, Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Houston, Texas
Dr. Ballantyne discloses that she receives grants and does research support for Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Pfizer, Otsuka, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda, NIH, AHA, and ADA. She also a consultant for Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, Matinas BioPharma, Merck, Novartis, Pfizer, Regeneron, Roche, and Sanofi-Synthelabo.
Daniel J. Rader, MD Seymour Gray Professor of Molecular Medicine Chair, Department of Genetics Chief, Division of Translational Medicine and Human Genetics, Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia, Pennsylvania
Dr. Rader discloses that he is a consultant for Aegerion, Eli Lilly, and Sanofi. He also holds a patent on lomitapide licensed to Aegerion.
Henry N. Ginsberg, MD Irving Professor of Medicine Director, Irving Institute for Clinical and Translational Research Columbia University Medical Center New York, New York
Dr. Ginsberg discloses that he receives grants and does research for Amgen, Merck, and Sanofi-Regeneron. He is also a consultant for Amgen, Astra-Zeneca, BMS, Kowa, Merck, and Sanofi.
Roger S. Blumenthal, MD Kenneth Jay Pollin Professor of Cardiology Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Johns Hopkins School of Medicine Baltimore, Maryland
Dr. Blumenthal has no financial relationships to disclose.
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
MER Content Managers have no financial relationships to disclose.
ECM: Patrick J. Crowley, MBA, President/CEO, Dina Kouveliotes, Account Manager, Jodi Andrews, VP, Operations, have no financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Educational Concepts in Medicine (ECM). MER is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 2.75 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 2.75 contact hours.
CE for Pharmacists
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy (0.275 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Program Number - 0816-9999-15-054-H01-P
Pharmacists should complete the entire activity in order to receive 2.75 contact hours.
This activity is certified as knowledge based CPE.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Educational Concepts in Medicine, and/or Sanofi. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Educational Concepts in Medicine, and/or Sanofi. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For information about the accreditation of this program, please contact Medical Education Resources at (800) 421-3756.